CCL20:银屑病疾病严重度、炎症与血管健康受损的潜在生物标志物
该研究在银屑病患者及年龄性别匹配对照中,用Olink多重蛋白组检测273种蛋白,并直接对肱静脉内皮细胞转录组分析血管内皮炎症。结果显示CCL20与血管内皮炎症相关(r=0.55,P<.001),校正混杂后仍显著(β=1.71,P=.02),并可在包含PASI、Framingham风险、hs-CRP、IL-17A和IL-6的模型基础上增加预测价值。
要点
- CCL20与银屑病血管内皮炎症强相关,强于IL-6与IL-17A。
- 校正混杂因素后CCL20与内皮炎症的关联仍显著。
- CCL20在已有PASI等指标的模型上增加预测价值。
核心结论
- CCL20表达与血管内皮炎症强相关,反映全身炎症,可能作为银屑病血管健康受损的潜在生物标志物。
研究设计与样本
- 观察性研究,纳入银屑病患者及年龄性别匹配对照,用Proseek Multiplex Cardiovascular disease与Inflammatory试剂盒分析273种蛋白。
- 通过肱静脉内皮细胞直接转录组分析测量血管内皮炎症与健康。
主要发现
- 银屑病患者中CCL20、IL-6、IL-17A为前三位循环促炎细胞因子。
- 血管内皮炎症与CCL20相关(r=0.55;P<.001),与IL-6相关较弱(r=0.36;P=.04),与IL-17A相关(r=0.29;P=.12)。
- 校正潜在混杂因素后,CCL20与血管内皮炎症的关联仍显著(β=1.71;P=.02)。
- 在嵌套模型中,CCL20在已含PASI、Framingham风险、hs-CRP、IL-17A和IL-6的模型(χ2=48.18;P<.001)基础上增加预测血管内皮炎症的价值(χ2=79.22;P<.001)。
临床怎么用
- 在银屑病评估中可关注CCL20作为反映全身炎症与血管健康受损的潜在补充标志物。
- CCL20可能辅助识别传统促炎标志物未捕获的心血管风险,但尚需进一步验证。
局限性
- 研究为观察性设计,无法对CCL20与心血管风险的关系作因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers. OBJECTIVE: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis. METHODS: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells. RESULTS: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (β = 1.71; P = .02). In nested models, CCL20 added value (χ2 = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ2 = 48.18; P < .001) in predicting vascular endothelial inflammation. LIMITATIONS: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk. CONCLUSION: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.
引用
- Elnabawi YA, Garshick MS, Tawil M, et al. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. J Am Acad Dermatol. 2020. PMID: 33259876. doi:10.1016/j.jaad.2020.10.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。